Physician profile
Lawrence Weinstein
NPI 1649291113
$5,467.52
in general payments reported to CMS, 2019-2025
26 companies · $784 in 2025
The $784 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $973 · 2021: $393 · 2022: $819 · 2023: $783 · 2024: $1,026 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $799.18 | 2019-2025 | |
| Medtronic Vascular, INC. | $668.68 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $612.20 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $430.64 | 2022-2025 | |
| Amgen INC. | $399.59 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $352.81 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $325.52 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $298.47 | 2019-2025 | |
| Boston Scientific Corporation | $292.20 | 2019-2025 | Watchman Flx, Varithena Administration Pack, Watchman Access System |
| Astrazeneca Pharmaceuticals Lp | $290.22 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $193.82 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $185.87 | 2022-2024 | Ensite, Aveir |
| Artivion, INC. | $103.27 | 2019-2020 | |
| Cvrx, INC. | $99.62 | 2024-2025 | Barostim Neo System |
| Atricure, INC. | $84.74 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $74.33 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $58.19 | 2024 | |
| Novo Nordisk INC | $32.43 | 2025 | Wegovy |
| Cashflow Solutions, LLC | $31.69 | 2022 | |
| Philips North America LLC | $27.06 | 2022 | |
| Medtronic, INC. | $26.02 | 2021 | |
| Lilly USA, LLC | $24.32 | 2025 | Zepbound |
| Sanofi-Aventis U.S. LLC | $21.77 | 2022 | |
| Irhythm Technologies, INC. | $18.59 | 2024 | Zio Xt Patch, Zio Monitor |
| Preventice Services, LLC | $16.29 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.